Welcome to our dedicated page for Strata Skin Sciences news (Ticker: SSKN), a resource for investors and traders seeking the latest updates and insights on Strata Skin Sciences stock.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) is a medical technology company focused on in-office dermatologic devices, and its news flow reflects that specialization. Company announcements frequently highlight developments related to its core technologies: the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClearX® Acne Therapy System. These updates often cover new clinical evidence, regulatory milestones, reimbursement decisions, and commercial expansion in dermatology markets.
Investors and clinicians following SSKN news can expect regular coverage of peer-reviewed studies involving XTRAC in conditions such as psoriasis, vitiligo, atopic dermatitis, and mycosis fungoides, including combination regimens with topical drugs and JAK inhibitors. STRATA frequently reports on published data that it believes support the safety, efficacy, and personalized use of excimer laser therapy across a range of inflammatory and autoimmune skin diseases.
News items also address reimbursement and policy developments. STRATA has issued releases on CMS Medicare Physician Fee Schedule decisions related to CPT® codes 96920–96922, including continued coverage, payment levels, and recognition of future code descriptor expansions for excimer laser procedures. These updates are relevant for understanding how reimbursement may influence utilization of XTRAC in U.S. dermatology clinics.
Corporate and capital markets updates are another recurring theme. STRATA uses news releases to communicate quarterly financial results, non-GAAP performance metrics, registered direct offerings, and at-the-market equity programs. The company also reports on its legal and competitive positioning, including litigation milestones against competing device manufacturers and the recapture of dermatology clinics into its XTRAC partnership network.
International growth initiatives, such as COFEPRIS clearance for TheraClearX in Mexico and partnerships with commercialization firms like MINO Labs, appear in STRATA’s news as the company expands its device-based acne and phototherapy offerings beyond the United States. For users of this SSKN news page, the feed provides an ongoing view into STRATA’s clinical, regulatory, commercial, and financial developments in the dermatology device space.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced the grant of equity-based awards to Robert Moccia, who has commenced his role as CEO and President. Effective March 1, 2021, Moccia received stock options to purchase 1,632,590 shares at a strike price of $1.73, vesting over three years. This decision supports the company's strategic goal to enhance its leadership in dermatology, particularly through its innovative treatment solutions like the XTRAC® excimer laser, which serves millions of patients with various skin conditions.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced the appointment of Robert Moccia as President and CEO, effective March 1, 2021, following the departure of Dolev Rafaeli, Ph.D. Moccia brings over three decades of experience in dermatology, previously founding Encore Dermatology and doubling revenues at Precision Dermatology, leading to a significant acquisition. The company plans to release its Q4 2020 financial results on March 24, 2021, aiming to enhance its position in the growing dermatology market through its innovative products and direct-to-consumer business model.
STRATA Skin Sciences reported preliminary fourth quarter revenues of $6.6 million to $6.8 million, down from $8.9 million in Q4 2019. Recurring revenues are projected between $5.0 million and $5.2 million, compared to $6.6 million a year prior. The company saw a net increase of 19 XTRAC systems placed domestically. Cash and cash equivalents rose to $18.0 million as of December 31, 2020. Despite challenges due to COVID-19, December 2020 marked the highest gross domestic billing month of the year. Final audited results will be released in late March.
STRATA Skin Sciences (NASDAQ: SSKN) has launched a new business, Home by XTRAC™, providing at-home treatment for skin diseases not eligible for in-office care. This service is insurance-reimbursed and leverages existing resources without significant costs. The company began initial shipments in 2020 and anticipates a positive revenue impact in 2021. The Home by XTRAC™ solution aims to meet the needs of patients with conditions like psoriasis, impacting over 31 million Americans. STRATA expects per patient reimbursements ranging from $1,316 to $5,163.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a leader in medical technology for dermatology, announced participation in the H.C. Wainwright BioConnect Virtual Conference from January 11 to January 14, 2021. The presentation will be available on demand starting January 11 on the Company’s website. STRATA develops innovative products like the XTRAC excimer laser, targeting dermatologic conditions such as psoriasis and vitiligo, impacting over 35 million Americans. The Company's unique DTC advertising model has expanded its network to over 813 clinics and over 2,000 devices globally, enhancing patient access to treatment.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) has renewed its debt through a one-year cash secured loan with Israel Discount Bank of New York at a fixed interest rate of 1.40%, due December 30, 2021. The company focuses on innovative dermatology products, including the XTRAC® excimer laser, used to treat conditions affecting over 35 million patients in the U.S. STRATA has expanded its dermatology partner network to over 813 clinics and maintains a worldwide installed base of over 2,000 devices, employing a direct-to-consumer advertising model.
STRATA Skin Sciences (SSKN) reported Q3 2020 revenue of $5.6 million, a 25% decline from $7.5 million in Q3 2019. Recurring revenue fell 35.9% year-over-year to $3.8 million but saw a 37.2% increase from Q2 2020. Gross margins dropped to 57.5% from 61.8% a year prior. The net loss was $1.3 million, or $0.04 per share, compared to a loss of $0.9 million, or $0.03 per share in Q3 2019. With 837 XTRAC devices installed, the company remains cautiously optimistic about growth despite COVID-19 challenges.
STRATA Skin Sciences, a medical technology company focused on dermatology, announced its participation in several upcoming investor conferences. Dr. Dolev Rafaeli and CFO Matthew Hill will present at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020, at 2:30 PM ET (virtual format), and the Oppenheimer MedTech Summit on the same day with 1x1 meetings. They will also attend the A.G.P. Virtual Healthcare Symposium on November 19, 2020, also focusing on 1x1 meetings. STRATA is known for its innovative XTRAC® excimer laser treatment technology, targeting skin conditions affecting over 35 million patients in the U.S.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) will release its third quarter financial results on November 10, 2020, prior to market opening. A conference call is scheduled for 8:30 AM ET to discuss the results and provide a corporate update. STRATA focuses on innovative dermatological treatments, including the XTRAC excimer laser system, which targets conditions like psoriasis and vitiligo. The Company has established a robust network of over 789 dermatology clinics, enhancing patient access to reimbursable treatment options.
STRATA Skin Sciences (NASDAQ: SSKN) announced a peer-reviewed study in the Journal of Drugs in Dermatology highlighting the cost-effectiveness and clinical efficacy of its XTRAC excimer laser for psoriasis. The study reveals that XTRAC provides faster results with fewer adverse events compared to traditional treatments, achieving up to 97% savings over biologic drugs. Patients experience shorter treatment durations and can attain remission without maintenance therapy. The results position XTRAC as a valuable alternative amid rising concerns over costly biologic therapies.